Plain-English translation of NCT07219602 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
The RUBENS trial is testing a new medication called obicetrapib, either alone or combined with another cholesterol-lowering drug called ezetimibe, to see if it can better control cholesterol and triglyceride levels in people with type 2 diabetes or metabolic syndrome. You would take this medication on top of the cholesterol-lowering drugs you may already be using. The study will measure how well the medication works and whether it is safe.
Many people with diabetes and metabolic syndrome struggle to get their cholesterol and triglycerides to healthy levels even when taking standard medications. Researchers believe this new treatment may help fill that gap and reduce heart disease risk in these patients.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will be randomly assigned to take either the new medication, a combination of the new medication with ezetimibe, or a placebo pill — all on top of your current cholesterol-lowering therapy. You will take your assigned pill once daily and attend regular visits to have blood tests and check-ups so the researchers can track how the treatment is working and watch for any side effects. The study includes a main phase and an option to continue on the combination medication in an open-label extension if desired.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States